EGCG Improves Acne by Modulating Molecular Targets

Not Applicable

Completed

• Conditions: Acne Vulgaris
• Interventions: Other: topical EGCG application on acne

• Registration Number: NCT01687556
• Lead Sponsor: Seoul National University Hospital

Brief Summary

Epigallocatechin-3-gallate (EGCG) may improve acne vulgaris

* major polyphenolic constituent in green tea

* known as potent anti-carcinogenic, anti-inflammatory, anti-proliferative, and antimicrobial activities

* lipid-lowering and antiandrogenic properties was reported

* EGCG can improve acne vulgaris via one of the above mentioned actions.

Detailed Description

Acne vulgaris is one of the most prevalent skin disorders of sebaceous follicles, affecting more than 85% of adolescents in United States. Acne can persist throughout the adulthood, and even a mild form of acne might progress to permanent scarring on the face, chest and back, thereby causing significant physical and psychosocial morbidities. Acne is a multifactorial disease of which etiology has not been fully elucidated, although considerable progress has been made in understanding its pathogenesis during last decade. The major pathogenic features of acne include abnormal ductal keratinization, sebum overproduction, Propionibacterium acnes, and inflammation. Common acne medications such as topical retinoids, antibiotics and isotretinoin are associated with irritation and incomplete responses, increased bacterial resistance or untoward side events, respectively. Thus there is a continuing need for a novel, effective agent targeting different aspects of acne pathogenesis, with minimal side effects.

In the recent decade, epigallocatechin-3-gallate (EGCG), the major polyphenolic constituent in green tea, has attracted much interest on account of its potent anti-carcinogenic, anti-inflammatory, anti-proliferative, and antimicrobial activities. Preclinical, observational, and clinical trial data have indicated that EGCG can inhibit tumor initiation, promotion, progression, and angiogenesis. EGCG also suppresses neutrophil chemotaxis, and has been suggested to improve many diseases that have inflammatory components such as diabetes, kidney injuries, arthritis, allergies, dental caries, cardiovascular, gastrointestinal, and neurodegenerative diseases. In skin, EGCG has been investigated mainly in light of antioxidative, immunopotentiating and anticarcinogenic properties against chemicals or ultraviolet irradiation. Moreover, EGCG has lipid-lowering and antiandrogenic properties, and can downregulate peroxisome proliferator-activated receptor-γ expression. Based on these observations, it can be inferred that EGCG might be effective in the treatment of acne.

Basic Information
|
Recruitment & Eligibility
|
Study & Design
|
Trial Locations

Study Timeline

• Study Start: 2005-07
• Primary Completion: 2006-06
• Study Completion: 2006-06
• Study First Submitted: 2010-07-23
• Status Verified: 2012-09
• Study First Submitted QC: 2012-09-13
• Last Update Submitted: 2012-09-13
• Study First Posted: 2012-09-19
• Last Update Posted: 2012-09-19

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 35

Inclusion Criteria

• age of at least 15 years
• clinical diagnosis of mild to moderate acne vulgaris

Read More

Exclusion Criteria

• known pregnancy or lactation
• any medical illness that might influence the results of the study,
• a previous history of oral acne medication or surgical procedures including laser treatment within 6 month and topical medication within 4 weeks of study enrollment.

Read More

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
topical EGCG 5%	topical EGCG application on acne	Eighteen subjects were designated to use 5% EGCG, to evaluate a dose-response relationship. Since baseline visits, affected areas of randomly allocated half sides were treated with 5% EGCG solution twice daily, whereas those of the opposite sides were treated with vehicle only (3% ethanol).
Topical EGCG 1%	topical EGCG application on acne	Seventeen subjects were designated to use 1% EGCG .Since baseline visits, affected areas of randomly allocated half sides were treated with 1% solution twice daily, whereas those of the opposite sides were treated with vehicle only (3% ethanol).

Primary Outcome Measures

Name	Time	Method
Assessment of acne severity	8 week after baseline	Lesion counts of non-inflammatory lesions (closed comedone, open comedone) and severity measured by Reeds revised scale

Secondary Outcome Measures

Name	Time	Method
2-mm punch biopsy of acne lesion on the EGCG-treated sides	8 week after baseline
Standardized clinical photographs	8 week after baseline

Trial Locations

Locations (1)

Department of Dermatology, Seoul National University College of Medicine,; 🇰🇷 Seoul, Korea, Republic of